Evidence map›Paper›PMID 34344397›Full record

ReviewOrphanet journal of rare diseases2021

Social and medical needs of rare metabolic patients: results from a MetabERN survey.

Sylvia Sestini, Laura Paneghetti, Christina Lampe, Gianni Betti, Simon Bond, Cinzia Maria Bellettato, Scarpa Maurizio

Abstract readReview
In one paragraph

Review in Orphanet journal of rare diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Alkaptonuria.Nature reviews. Disease primers · 2024
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sylvia SestiniItalian Association of Patients With Alkaptonuria (aimAKU), Siena, Italy.
Laura PaneghettiRegional Coordinating Center for Rare Diseases, MetabERN, Udine University Hospital, Udine, Italy.
Christina LampeCenter for Rare Diseases Giessen (ZSEGI), Department of Child Neurology, Justus-Liebig University, Giessen, Germany.
Gianni BettiDepartment of Economics and Statistics, University of Siena, Siena, Italy.
Simon BondRegional Coordinating Center for Rare Diseases, MetabERN, Udine University Hospital, Udine, Italy.
Cinzia Maria BellettatoRegional Coordinating Center for Rare Diseases, MetabERN, Udine University Hospital, Udine, Italy.
Scarpa MaurizioRegional Coordinating Center for Rare Diseases, MetabERN, Udine University Hospital, Udine, Italy. maurizio.scarpa@metab.ern-net.eu.ORCID 0000-0002-0382-3251

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMany surveys have been performed over the years to assess the medical and social requirements of patients with a rare disease, but no studies have focused specifically on patients in Europe or with an inherited metabolic disease (IMD). To obtain a comprehensive overview of the social and psychological status and needs of IMD patients, especially in Europe, the European Reference Network for Hereditary Metabolic Disorders (MetabERN) has performed a dedicated survey among its metabolic patients.

resultsA total of 924 patients and caregivers responded to the questionnaire. Most participants were from 25 European countries, with Spain, Italy, and Germany being the most represented; only eight participants were extra-European. The survey showed that most social assistance services, from free educational/development services for those with intellectual disability to transition from childhood to adult care and job placement support, are available for a limited number of patients or are unknown to the majority of patients or their parents/caregivers. Similarly, psychological assistance for the patient or the parent/caregiver is available for a small fraction of respondents, despite the fact that the majority considers this type of support necessary for both the patient and the caregiver. In addition, for most IMD patients local specialised or emergency medical assistance is lacking, although national clinical pathways are defined, and medical professionals of reference are readily available when needed. Lastly, while most national health services in Europe cover all or part of the expenses for medications, medical devices, food supplements, dietary integrators, physiotherapy, and speech therapy, significant gaps in the economic support for healthcare and other expenses still exist.

conclusionsOverall, our survey reveals a widespread lack of social, psychological, and economic support for IMD patients in Europe. More needs to be done to provide daily assistance to IMD patients in order to alleviate the burden on caregivers and to allow patients to become independent and productive adults. Where support is actually available locally or nationally, most IMD patients are not aware of it, so an active dissemination of this information among the metabolic community is essential.

Indexed as

CaregiversParentsAdultChildGermanyHumansRare DiseasesSurveys and QuestionnairesIMDsInherited metabolic diseasesPsychological supportRare diseasesSocial services

Identifiers

PMID34344397
PMCPMC8329639

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.